amphotericin b methyl ester
Recently Published Documents


TOTAL DOCUMENTS

68
(FIVE YEARS 2)

H-INDEX

19
(FIVE YEARS 1)

Biochemistry ◽  
2019 ◽  
Vol 58 (17) ◽  
pp. 2282-2291 ◽  
Author(s):  
Tomoya Yamamoto ◽  
Yuichi Umegawa ◽  
Masaki Yamagami ◽  
Taiga Suzuki ◽  
Hiroshi Tsuchikawa ◽  
...  

2009 ◽  
Vol 84 (6) ◽  
pp. 3121-3126 ◽  
Author(s):  
Abdul A. Waheed ◽  
Sherimay D. Ablan ◽  
Raymond C. Sowder ◽  
James D. Roser ◽  
Carl P. Schaffner ◽  
...  

ABSTRACT We previously reported that human immunodeficiency virus type 1 (HIV-1) develops resistance to the cholesterol-binding compound amphotericin B methyl ester (AME) by acquiring mutations (P203L and S205L) in the cytoplasmic tail of the transmembrane envelope glycoprotein gp41 that create cleavage sites for the viral protease (PR). In the present study, we observed that a PR inhibitor-resistant (PIR) HIV-1 mutant is unable to efficiently cleave the gp41 cytoplasmic tail in P203L and S205L virions, resulting in loss of AME resistance. To define the pathway to AME resistance in the context of the PIR PR, we selected for resistance with an HIV-1 isolate expressing the mutant enzyme. We identified a new gp41 mutation, R236L, that results in cleavage of the gp41 tail by the PIR PR. These results highlight the central role of gp41 cleavage as the primary mechanism of AME resistance.


2009 ◽  
Vol 15 (29) ◽  
pp. 7117-7128 ◽  
Author(s):  
Alex M. Szpilman ◽  
Damiano M. Cereghetti ◽  
Jeffrey M. Manthorpe ◽  
Nicholas R. Wurtz ◽  
Erick M. Carreira

2009 ◽  
Vol 38 (2) ◽  
pp. 114-115 ◽  
Author(s):  
Naohiro Matsushita ◽  
Yukiko Matsuo ◽  
Hiroshi Tsuchikawa ◽  
Nobuaki Matsumori ◽  
Michio Murata ◽  
...  

2008 ◽  
Vol 82 (19) ◽  
pp. 9776-9781 ◽  
Author(s):  
Abdul A. Waheed ◽  
Sherimay D. Ablan ◽  
Ferri Soheilian ◽  
Kunio Nagashima ◽  
Akira Ono ◽  
...  

ABSTRACT We investigated the mechanism by which the cholesterol-binding compound amphotericin B methyl ester (AME) inhibits human immunodeficiency virus type 1 (HIV-1) particle production. We observed no significant effect of AME on Gag binding to the plasma membrane, Gag association with lipid rafts, or Gag multimerization, indicating that the mechanism of inhibition by AME is distinct from that by cholesterol depletion. Electron microscopy analysis indicated that AME significantly disrupts virion morphology. Interestingly, we found that AME does not inhibit the release of Vpu-defective HIV-1 or Vpu− retroviruses such as murine leukemia virus and simian immunodeficiency virus. We demonstrated that the ability of Vpu to counter the activity of CD317/BST-2/tetherin is markedly reduced by AME. These results indicate that AME interferes with the anti-CD317/BST-2/tetherin function of Vpu.


2008 ◽  
Vol 120 (23) ◽  
pp. 4411-4414 ◽  
Author(s):  
Alex M. Szpilman ◽  
Jeffrey M. Manthorpe ◽  
Erick M. Carreira

Sign in / Sign up

Export Citation Format

Share Document